Indication
Pulmonary Alveolar Proteinosis
3 clinical trials
2 products
2 drugs
Clinical trial
Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) InfectionStatus: , Estimated PCD: 2023-08-01
Product
Liberase EnzymeProduct
Sterile Normal SalineClinical trial
Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated DiseasesStatus: Completed, Estimated PCD: 2021-05-06
Drug
VarlilumabClinical trial
Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisStatus: Completed, Estimated PCD: 2009-07-01
Drug
rituximab